Clinical Study

A Randomized, Double-Blinded, Placebo-Controlled Phase II Study Of Adjuvant Everolimus Following The Resection Of Metastatic Pancreatic Neuroendocrine

Posted Date: May 15, 2019

  • Investigator: Shimul Shah
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects of using the study drug, everolimus (also known as Afinitor), along with the usual monitoring after surgical removal of pancreatic neuroendocrine cancer tumor that has spread to the liver, to using the usual monitoring alone after surg

Criteria:

To Be Eligible, You Must Have Histologically Or Pathologically Confirmed Metastatic Low Or Intermedi

Keywords:

Liver, Cancer, Tumors, E2212, Pancreas

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.